........... Now, here’s the remarkable and truly astonishing thing about Multikine: the company developing this science believes that it has created a 4th treatment modality—immunotherapy delivered at the site of the primary tumor. No other company but CEL-SCI is pursuing this novel approach, as all other cancer immunotherapy is directed at recurrent cancer in patients. This is the specific revolutionary thrust of the CEL-SCI research and treatment construct. CEL-SCI hopes to use its focused immunotherapy to increase the “cure rate” and to potentially eliminate, or at least drastically reduce, the untoward and dreadful treatment modalities currently in use as the standard of care.
Slightly off-topic but relevant as a comparable treatment evolution, consider how HIV/AIDS just a few years ago was looked at as a disease with a 100% dire prognosis. A single drug, zidovudine, was discovered that seemed to help those afflicted. Then, after a massive input of research, a combination therapy (i.e. a “cocktail” of drugs) was advanced in an accelerated FDA category to treat the disease to the point where the HIV antibody doesn’t show in blood tests at all (as long as the drug combination is taken by the patient in a very disciplined regimen). Gilead Sciences (GILD) developed one of those HIV cocktails and the shares of the company went from $0.27 to now over $100, with a market-cap of now $150 billion and sales of over $24 billion a year. Such is the reward—or “golden ring”—at the successful end of treating a condition once considered “untreatable” whose afflicted were doomed.
Similarly, the hepatitis C combination therapy is thought to cure 96% of those patients who did not already have cirrhosis or liver cancer. Key players are AbbVie (ABBV) NYSE – (market-cap of $90 billion with sales of over $19 billion) and Gilead Sciences (GILD), here again at the forefront. Hepatitis C is another terrible condition that now is treatable with a combination therapy.